Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Subjective experience and mental side-effects of antipsychotic treatment.

Gerlach J, Larsen EB.

Acta Psychiatr Scand Suppl. 1999;395:113-7.

PMID:
10225340
3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

[Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].

Haefliger T, Bonsack C.

Encephale. 2006 Jan-Feb;32(1 Pt 1):97-105. French.

PMID:
16633296
5.

Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects.

Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW.

J Clin Psychiatry. 2004 Jul;65(7):932-9.

PMID:
15291682
6.

The science of antipsychotics: mechanistic insight.

Tamminga CA.

CNS Spectr. 2003 Nov;8(11 Suppl 2):5-9.

PMID:
14978451
7.

EPS profiles: the atypical antipsychotics are not all the same.

Weiden PJ.

J Psychiatr Pract. 2007 Jan;13(1):13-24. Review.

PMID:
17242588
8.

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.

Plesnicar BK, Zalar B, Breskvar K, Dolzan V.

J Psychopharmacol. 2006 Nov;20(6):829-33. Epub 2006 Feb 14.

PMID:
16478753
10.

Switching to amisulpride.

Peuskens J.

Curr Med Res Opin. 2002;18 Suppl 3:s23-8. Review.

PMID:
12418609
11.

Motor and mental side effects of clozapine.

Gerlach J, Peacock L.

J Clin Psychiatry. 1994 Sep;55 Suppl B:107-9.

PMID:
7961551
12.

Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.

Lambert M, Schimmelmann BG, Karow A, Naber D.

Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S181-90. Review.

PMID:
14677077
13.

Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence.

Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, Golks D, Naber D.

Eur Psychiatry. 2004 Nov;19(7):415-22.

PMID:
15504648
14.

Motor and mental aspects of extrapyramidal syndromes.

Casey DE.

Int Clin Psychopharmacol. 1995 Sep;10 Suppl 3:105-14. Review.

PMID:
8866772
15.

Predictors of subjective and objective quality of life in outpatients with schizophrenia.

Yamauchi K, Aki H, Tomotake M, Iga J, Numata S, Motoki I, Izaki Y, Tayoshi S, Kinouchi S, Sumitani S, Tayoshi S, Takikawa Y, Kaneda Y, Taniguchi T, Ishimoto Y, Ueno S, Ohmori T.

Psychiatry Clin Neurosci. 2008 Aug;62(4):404-11. doi: 10.1111/j.1440-1819.2008.01818.x.

16.

Overcoming the neuroleptic-induced deficit syndrome: clinical observations with remoxipride.

Lewander T.

Acta Psychiatr Scand Suppl. 1994;380:64-7. Review.

PMID:
7914053
17.

Iatrogenic disorders associated with conventional vs. atypical antipsychotics.

Nasrallah HA, Mulvihill T.

Ann Clin Psychiatry. 2001 Dec;13(4):215-27. Review.

PMID:
11958363
18.

Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.

Ritsner M, Perelroyzen G, Ilan H, Gibel A.

J Clin Psychopharmacol. 2004 Jun;24(3):245-54.

PMID:
15118477
19.

How much do novel antipsychotics benefit the patients?

Kasper S.

Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S71-7. Review.

PMID:
9690974
20.

Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight.

Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC.

J Clin Psychiatry. 2004 Oct;65(10):1372-6.

PMID:
15491241

Supplemental Content

Support Center